Cargando…

In silico identification of vaccine targets for 2019-nCoV

Background: The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China. Methods: The 2019 novel coronavirus prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chloe H., Koohy, Hashem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111504/
https://www.ncbi.nlm.nih.gov/pubmed/32269766
http://dx.doi.org/10.12688/f1000research.22507.2
_version_ 1783513302467346432
author Lee, Chloe H.
Koohy, Hashem
author_facet Lee, Chloe H.
Koohy, Hashem
author_sort Lee, Chloe H.
collection PubMed
description Background: The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China. Methods: The 2019 novel coronavirus proteome was aligned to a curated database of viral immunogenic peptides. The immunogenicity of detected peptides and their binding potential to HLA alleles was predicted by immunogenicity predictive models and NetMHCpan 4.0. Results: We report in silico identification of a comprehensive list of immunogenic peptides that can be used as potential targets for 2019 novel coronavirus (2019-nCoV) vaccine development. First, we found 28 nCoV peptides identical to Severe acute respiratory syndrome-related coronavirus (SARS CoV) that have previously been characterized immunogenic by T cell assays. Second, we identified 48 nCoV peptides having a high degree of similarity with immunogenic peptides deposited in The Immune Epitope Database (IEDB). Lastly, we conducted a de novo search of 2019-nCoV 9-mer peptides that i) bind to common HLA alleles in Chinese and European population and ii) have T Cell Receptor (TCR) recognition potential by positional weight matrices and a recently developed immunogenicity algorithm, iPred, and identified in total 63 peptides with a high immunogenicity potential. Conclusions: Given the limited time and resources to develop vaccine and treatments for 2019-nCoV, our work provides a shortlist of candidates for experimental validation and thus can accelerate development pipeline.
format Online
Article
Text
id pubmed-7111504
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-71115042020-04-07 In silico identification of vaccine targets for 2019-nCoV Lee, Chloe H. Koohy, Hashem F1000Res Research Article Background: The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China. Methods: The 2019 novel coronavirus proteome was aligned to a curated database of viral immunogenic peptides. The immunogenicity of detected peptides and their binding potential to HLA alleles was predicted by immunogenicity predictive models and NetMHCpan 4.0. Results: We report in silico identification of a comprehensive list of immunogenic peptides that can be used as potential targets for 2019 novel coronavirus (2019-nCoV) vaccine development. First, we found 28 nCoV peptides identical to Severe acute respiratory syndrome-related coronavirus (SARS CoV) that have previously been characterized immunogenic by T cell assays. Second, we identified 48 nCoV peptides having a high degree of similarity with immunogenic peptides deposited in The Immune Epitope Database (IEDB). Lastly, we conducted a de novo search of 2019-nCoV 9-mer peptides that i) bind to common HLA alleles in Chinese and European population and ii) have T Cell Receptor (TCR) recognition potential by positional weight matrices and a recently developed immunogenicity algorithm, iPred, and identified in total 63 peptides with a high immunogenicity potential. Conclusions: Given the limited time and resources to develop vaccine and treatments for 2019-nCoV, our work provides a shortlist of candidates for experimental validation and thus can accelerate development pipeline. F1000 Research Limited 2020-04-14 /pmc/articles/PMC7111504/ /pubmed/32269766 http://dx.doi.org/10.12688/f1000research.22507.2 Text en Copyright: © 2020 Lee CH and Koohy H http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lee, Chloe H.
Koohy, Hashem
In silico identification of vaccine targets for 2019-nCoV
title In silico identification of vaccine targets for 2019-nCoV
title_full In silico identification of vaccine targets for 2019-nCoV
title_fullStr In silico identification of vaccine targets for 2019-nCoV
title_full_unstemmed In silico identification of vaccine targets for 2019-nCoV
title_short In silico identification of vaccine targets for 2019-nCoV
title_sort in silico identification of vaccine targets for 2019-ncov
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111504/
https://www.ncbi.nlm.nih.gov/pubmed/32269766
http://dx.doi.org/10.12688/f1000research.22507.2
work_keys_str_mv AT leechloeh insilicoidentificationofvaccinetargetsfor2019ncov
AT koohyhashem insilicoidentificationofvaccinetargetsfor2019ncov